IFNα induces CCR5 in CD4

Journal

Research square
Titre abrégé: Res Sq
Pays: United States
ID NLM: 101768035

Informations de publication

Date de publication:
11 May 2023
Historique:
pubmed: 22 5 2023
medline: 22 5 2023
entrez: 22 5 2023
Statut: epublish

Résumé

Like EC, we find that ART-treated patients control serum IFNα concentration and show few immune cell alterations enabling a healthy but fragile medical status. However, treatment interruption leads to elevated IFNα reflecting virus production indicating that like EC, ART does not achieve a virological cure. The immune system becomes overwhelmed by multiple immune cell abnormalities as found in untreated patients. These are chiefly mediated by elevated IFNα inducing signaling checkpoints abnormalities, including PD1, in cytotoxic immune cells. Importantly, during acute infection, elevated IFNα correlated with HIV load and we found that IFNα enhances CCR5, the HIV coreceptor in CD4

Identifiants

DOI: 10.21203/rs.3.rs-2813616/v1 PMID: 37214795 PMC: PMC10197818
pubmed: 37214795
doi: 10.21203/rs.3.rs-2813616/v1
pmc: PMC10197818
pii:
doi:

Types de publication

Preprint

Langues

eng

Déclaration de conflit d'intérêts

Additional Declarations: There is NO Competing Interest.

Auteurs

Hélène Le Buanec (H)

Université de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010 Paris, France.

Valérie Schiavon (V)

Université de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010 Paris, France.

Marine Merandet (M)

Université de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010 Paris, France.

Alexandre How-Kit (A)

Laboratory for Genomics Foundation Jean Dausset-CEPH; Paris France.

Hongshuo Song (H)

Institute of Human Virology, School of Medicine, University of Maryland; Baltimore MD, 21201, USA, Department of Medicine, School of Medicine, University of Maryland, Baltimore, MD, 21201, USA.

David Bergerat (D)

Université de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010 Paris, France.

Céline Fombellida-Lopez (C)

Laboratory of Infectious Diseases, GIGA-I3, GIGA-Institute University of Liege; 4000 Liege, Belgium.

Armand Bensussan (A)

Université de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010 Paris, France.
ORCID: 0000-0002-0409-2497

Jean-David Bouaziz (JD)

Université de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010 Paris, France.
Dermatology Department, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.

Arsène Burny (A)

Laboratory of Molecular Biology, Gembloux Agrobiotech,University of Liège ;Belgium.
Global Virus Network, Baltimore, MD 21201, USA.

Gilles Darcis (G)

Laboratory of Infectious Diseases, GIGA-I3, GIGA-Institute University of Liege; 4000 Liege, Belgium.

Mohammad M Sajadi (MM)

Institute of Human Virology, School of Medicine, University of Maryland; Baltimore MD, 21201, USA, Department of Medicine, School of Medicine, University of Maryland, Baltimore, MD, 21201, USA.
Global Virus Network, Baltimore, MD 21201, USA.

Shyamasundaran Kottilil (S)

Institute of Human Virology, School of Medicine, University of Maryland; Baltimore MD, 21201, USA, Department of Medicine, School of Medicine, University of Maryland, Baltimore, MD, 21201, USA.
Global Virus Network, Baltimore, MD 21201, USA.
University of Maryland School of Medicine; Baltimore, MD 21201, USA, Program in Oncology, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD 21201, USA.

Daniel Zagury (D)

21CBIO ; Paris France.

Robert C Gallo (RC)

Institute of Human Virology, School of Medicine, University of Maryland; Baltimore MD, 21201, USA, Department of Medicine, School of Medicine, University of Maryland, Baltimore, MD, 21201, USA.
Global Virus Network, Baltimore, MD 21201, USA.

Classifications MeSH